Novavax Nuvaxovidâ¢ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17
- Nuvaxovidâ¢ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe
GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovidâ¢ (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged 12 through 17. The approval follows the positive recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 23, 2022.
"With this authorization, we are extremely pleased to be able to offer our Nuvaxovid COVID-19 vaccine to adolescents in the EU," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Our protein-based vaccine was developed using an innovative approach to traditional technology and has demonstrated efficacy and safety in both adolescents and adults."
The authorization was based on data from the ongoing pediatric expansion of PREVENT-19, a pivotal Phase 3 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the U.S., to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid. In the trial, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.
Preliminary safety data from the trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise. There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. No new safety signal was observed through the placebo-controlled portion of the study.
The EC granted CMA for Nuvaxovid to prevent COVID-19 in individuals aged 18 and over in December 2021. In addition to the EC's expanded CMA, India has granted emergency use authorization in the 12 through 17 year-old population.
Authorization in the U.S.
NVX-CoV2373 has not yet been authorized for use in the U.S. and the trade name Nuvaxovidâ¢ has not yet been approved by the U.S. Food and Drug Administration.
Important Safety Information
- Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
- Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at least 15 minutes is recommended and a second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid.
- Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stressârelated reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
- Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
- Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
- The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
- Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
- The effects with Nuvaxovid may temporarily affect the ability to drive or use machines.
- Individuals may not be fully protected until seven days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients.
- The most common adverse reactions observed during clinical studies were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise.
For additional information on Nuvaxovid, please visit the following websites:
NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-Mâ¢ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
The Novavax COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2 °- 8 ° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.
Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.
About the NVX-CoV2373 Phase 3 Trials
NVX-CoV2373 continues being evaluated in two pivotal Phase 3 trials.
PREVENT-19 (theâ¯PRE-fusion protein subunitâ¯Vaccineâ¯Efficacyâ¯Novavaxâ¯Trial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations inâ¯the U.S.â¯andâ¯Mexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, NVX-CoV2373 achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in theâ¯New England Journal of Medicineâ¯(NEJM).
The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of NVX-CoV2373 with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the United States, compared with placebo. In the pediatric trial, NVX-CoV2373 achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S.â¯Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.
PREVENT-19 is being conducted with support from the U.S. government, including the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health at HHS. BARDA is providing up toâ¯$1.75 billionâ¯under a Department of Defense agreement (# MCDC2011-001).
Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in NEJM.
About Matrix-Mâ¢ Adjuvant
Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide and will soon be under review in the U.S. for use in adults, adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.â¯
For more information, visitâ¯www.novavax.comâ¯and connect with us on LinkedIn.
*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.â¯
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, a COVID-seasonal influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for adolescents, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, and the efficacy, safety and intended utilization of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Alex Delacroix | 240-268-2022
Ali Chartan | 240-720-7804
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
More News by PR Newswire India
China Wuling's First Global Electric Vehicle Air ev Rollouted, First Step In Indonesia
FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID
GIGABYTE Releases 600 series BIOS updates ready for Intel's upcoming new-gen processors
Starburst Celebrates 10th Anniversary of Trino
Point-of-Care Ultrasound Certification Academy to Host World Conference
The "Picturesque and Dynamic Zhejiang" Global Short Video Competition Launches
BlackBerry Commended by Frost & Sullivan for Optimizing Edge-to-cloud Performance, Security, Privacy, and Scalability with its IVY Platform for Automakers
Amwell Applauded by Frost & Sullivan for its Comprehensive Digital Care Delivery Enablement Platform, Convergeâ¢
Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio
Axis Bank in partnership with CRMNEXT wins the Best CRM Implementation Award by Asian Banker
Godrej Properties Ltd. unveils insights from Home Livability Factors research
Gear Up with All New Helix Metalfit 3.0 Smartwatch Launched by Timex Group India
Roundtable with Leading Doctors and Youth Aims for a Tobacco-Free Future for India
Catalytic Investment to Improve Community Health Care for Millions Across Africa
DIFC Launches First Global Family Business and Private Wealth Centre
2022 ITOE - Home Lifestyle Expo Opens, Provides Strong Impetus for Development of Digital Trade
FRIMLINE LAUNCHES INDIA'S 1st ORAL CARE RANGE FOR PREGNANT WOMEN
Aptus Value Housing Finance India Limited announces Q1 FY23 Results
Tata Communications enhances InstaCCâ¢ Platform with digital features
/C O R R E C T I O N -- Lentra/
Leading Solar Energy Solution Provider Haitai Solar Launches IPO on Beijing Stock Exchange
Kiko Live to be launched on ONDC in September
Clarivate Selected by Singapore's National Library Board to Play a Part in Building Libraries of the Future
TCL Reaffirms its Leadership in Mini LED TVs in 2022
NID Foundation unveils Heartfelt-The Legacy of Faith; A book showcasing PM Modi's relationship with the Sikh community at Melbourne
AirCarbon Exchange Offsets Emissions Through to December 2023
Celebrate independence from the worries of interest rates with Tata Housing Development Company's 'Its Interesting' campaign with 3.50% interest rate for 12 months in the 75th year of Independence
Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development
M/V Riva Wind and M/V Arizona Both Sail from Ukraine with 105,000 Tons of Grain
Atlanta Site Strengthens Sims Lifecycle Services' Operational Footprint
PRA Group Leader LaTisha Tarrant Named Chief Human Resources Officer
Media Advisory - BMO Financial Group to Announce its Third Quarter 2022 Results
Vieworks Wins FDA Approval for Its Newest VIVIX-S F series
GACL Financial results for the first quarter ended 30th June 2022
Strong Technical Advantages of TANK Platform, GWM TANK300 Will Bring a New Intelligent Off-road Experience
Bitget Launches $200 Million Protection Fund To Safeguard Users' Asset Security
Chandigarh University joins hands with Punjab Remote Sensing Centre for resources management and disaster mitigation
Saudi Arabia to Bid for the 2026 AFC Women's Asian Cup
FIRMENICH DELIVERS RECORD RESULTS DESPITE CHALLENGING MACRO-ECONOMIC ENVIRONMENT
A Center of Hope and New Life
CHAIRMAN OF ATLAS CORP., FAIRFAX FINANCIAL HOLDINGS LIMITED AND THE WASHINGTON FAMILY PARTNER WITH OCEAN NETWORK EXPRESS PTE. LTD. TO JOINTLY PROPOSE ACQUIRING ALL COMMON SHARES OF ATLAS CORP. NOT CONTROLLED BY ITS MAJORITY SHAREHOLDERS FOR $14.45 PER SHARE IN CASH
Hon'ble Prime Minister Modi inaugurates multispecialty charitable Shrimad Rajchandra Hospital; a revolution in rural healthcare
PARAMOUNT PICTURES' "TOP GUN: MAVERICK" FLIES PAST $50 MILLION IN SCREENX AND 4DX
Empowering Young Women and Refugees Worldwide through STEM & Sustainability
ViewSonic's Visual Solutions Ignite Love and Hope in 2022 World Women's Art Festival
Besrey Celebrates Seventh Anniversary with Giveaways and Gifts for Parents
ADVENTURERS ROSS EDGLEY AND KATIE TUNN OPEN DOORS AT NEW TALISKER VISITOR EXPERIENCE
Frost & Sullivan Institute lauds Global Companies with Prestigious Enlightened Growth Leadership Awards
Oracle Names WorkForce Software the Cloud HCM ISV Partner of the Year as Winner of the 2021 Oracle Cloud HCM HR Heroes Visionary Award
In a first of its kind, Rural Banking Outlets in India to get a distinct identity through 'RedBlue Revolution'
Titan.ium Platform, LLC Announces 5G SA Evolution of NetCore to Expand Its Private Networks Solutions
Dentsu Group Acquires a Majority Stake in Extentia to Strengthen Customer Transformation and Technology Capabilities
Agility Completes Â£763 Million Acquisition of Menzies Aviation
Elearnmarkets goes global with their 2nd edition of the Face2Face Trading Conclave in Bangkok
Global Tree presents Study Fair 2022
Innoviti joins ONDC platform to help small sellers accelerate sales through co-promotion opportunities with banks and brands
VNPT Group partners with Comviva to deliver advanced digital customer experience
SVKM'S NMIMS Shirpur campus bags NBA accreditation for School of Pharmacy & Technology Management
Crest, an Inventory Planning Tool Gets Funding from Its first 2 Customers, Sirona Hygiene and Samosa Party
Panchshil Realty To Sponsor Accomplished Mountaineer Baljeet Kaur's Next Adventure
The Adecco Group: HALF YEAR REPORT 2022
The Adecco Group: Q2 22 Results - Market share momentum, solid growth and margin
Cielo continues global expansion, opens new office in India
VCTI Achieves Dramatic Growth Fueled by U.S.'s Plans and Funding for Broadband Expansion
Sun Life Appoints Chris Wei to EVP and Chief Client and Innovation Officer
ROSHN signs agreement to sponsor and rename Jeddah Waterfront
GameChange Solar Announces 6 GW Midwest Tracker Factory, Increases USA Capacity to 14 GW
Franklin Templeton, Inc. Renews with Empire State Realty Trust for 79k Square Feet at 100 First Stamford Place
Music industry veteran Lefroy Verghese joins Audio Network
Women's World Banking Announces 2023 Fintech Innovation Challenge to Elevate Fintechs with New Solutions to Close the Gender Gap in Financial Services
KPM Analytics Introduces New Discrete Analyzer to Complete Its SmartChemÂ® Product Line
HAVAS HEALTH & YOU PARTNERS WITH REPUBLICA HAVAS TO CREATE REPUBLICA HAVAS HEALTH
Collaboration of ePayLater, the SME Credit Platform with JioMart Partner
Firmenich Appoints Maurizio Clementi ad interim President of its Taste & Beyond Division
Enfinity Global closes $242 million of long term financing for three operational solar power plants in Japan
HIGHLIGHTS FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2022
HISTORY OF HYPERTENSIVE DISORDERS DURING PREGNANCY LINKED TO INCREASED RISK OF DEMENTIA
HarperCollins Publishers India is proud to announce the forthcoming publication of Chitra Banerjee Divakaruni's new novel INDEPENDENCE
Waterborne Trade in Rio South Texas
A Bond Tightly Woven Together With Sneh - An Exquisite Rakhi Range From Ferns N Petals (FNP)
FMCG and Consulting companies top recruiters at SPJIMR Autumn Internship 2022
Jury unveiled for UXplorer'22; features design industry stalwarts from India and abroad
Hisense Shines in UEFA Women's EURO 2022â¢, Achieved Champion Position in Global Market
The Israeli Ministry of Defense Selects Mona's Enterprise Monitoring Solution to Gain Complete Visibility into Their AI / ML Systems
Over 22% of small businesses that availed loans in FY 2022 were run by women: NeoGrowth Social Impact Report
FORTUNE RELEASES ANNUAL FORTUNE GLOBAL 500 LIST
Technology Solutions to Boost Employee Experience and Improve Patient Outcomes
Cendyn announces acquisition of digitalhotelier
Credgenics launches Digital Collections Technology Platform in Indonesia
MOMENTUM NAMED A BEST COMPANY TO WORK FOR WITH "OUTSTANDING" LEVELS OF WORKPLACE ENGAGEMENT
Zimyo at-service with its 'Start-up Program'
Sanjay Ghodawat conferred with the Maharashtra Leadership Award 2022
Jio Platforms partners with Subex HyperSense AI to augment its 5G product line
Globalization Partners Again Named an Industry Leader in NelsonHall's 2022 Global Employer of Record Research
Detect Technologies announces global agreement with Vedanta
CLA Nearly Triples Office Space with ESRT at One Grand Central Place
Sparrow Introduces Newly Updated Sparrow Cloud and Sparrow SCA at Black Hat USA 2022
CELEBRATING CULTURAL REVIVAL AND THE TRADITION OF PASSING ON GENERATIONAL KNOWLEDGE THROUGH A NEW ROYAL CANADIAN MINT COIN HONOURING THE RED RIVER MÃTIS
LOWER SOCIOECONOMIC STATUS IN CHILDHOOD, PERSISTENT LOW WAGES LINKED TO RISK FOR DEMENTIA AND FASTER MEMORY DECLINE
Expel Applauded by Frost & Sullivan for Enabling Managed and Automated Threat Detection and Response
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Bigtincan Unveils Analytics Experience and Delivers Enhancements to Award-Winning Sales Enablement Platform
Zift Solutions Marks Six Years of SOC 2 Compliance
Adorable has a new meaning with Little Surprise Box the pioneers of Kids Monsoon Fashion in India
Firmenich Announces Grand Opening of West Coast Pilot Plant for Food & Beverage Customers
Leica Camera engages in the Laser TV equipment segment and agrees on technological cooperation with Hisense
Metabolon Awarded ISO 9001:2015 Recertification
At Chandigarh University, multiple scholarships worth Crores of rupees help talented and meritorious students overcome the barrier of weaker economic situation
Altair Announces Winners of 10th Annual Enlighten Award
iHerb Achieves Customer Service Milestones
10,000 RMB! "My Guangdong Story" short video solicitation calls for global entries
STL launches comprehensive optical suite for India's 5G readiness
LambdaTest's intelligent test orchestration platform HyperExecute is now available on the Microsoft Azure Marketplace
Northwest Analytics Applauded by Frost & Sullivan for Preventing Institutional Knowledge Loss and Bridging Skills Gaps with NWA Analytics Knowledge Suiteâ¢
New Research Reveals Risk Factors to Business Success in a Post-Pandemic World
Comviva receives Mastercard Cloud Based Payments Certification
EZVIZ LAUNCHES TY1 With 4MP, A SMART Wi-Fi PAN and TILT CAMERA
Novel and fast typing method developed to control monkeypox by Molecular Biology Systems (MBS) in collaboration with the Amsterdam UMC and Danish Rigshospitalet
Intersec Reports Most Successful Fiscal Year In Company History
Protean forays into cyber security business, launches Protean InfoSec Services Limited
Prudent Corporate Advisory Services Limited Profits grew by 25% YoY & Flows from SIPs Reach Highest Ever in Q1FY23
Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency
SEERIST ESTABLISHES THE FIRST AUGMENTED ANALYTICS TECHNOLOGY FOR SECURITY AND THREAT INTELLIGENCE PROFESSIONALS
Quinnox named a Strong Performer in Modern Application Development Services by Independent Analyst Firm
Tech Mahindra Announces Strategic Partnership with Soroco to Establish a Large Task Mining Center of Excellence
Eventbrite Welcomes Sapna Nair as Managing Director and VP of Engineering in India
PNY launches XLR8 Gaming EPIC-X RGB(TM) DDR4 Silver 3200MHz and 3600MHz desktop memory
The Benefits of a Smart Connected Commerce for MSMEs in APAC
Allied UniversalÂ® Expands By 22,000 Square Feet with Empire State Realty Trust at 501 Seventh Avenue
Ithra's Hijrah: In the Footsteps of the Prophet exhibit revisits the birth of Islam from a modern perspective
New initiative from Turkish Airlines to combat climate change: Co2mission
EXPERIENCES OF RACISM ASSOCIATED WITH POOR MEMORY, INCREASED COGNITIVE DECLINE
INEOS STYROLUTION SELLS ITS ENTIRE EQUITY INTEREST IN INEOS STYROLUTION INDIA
IMG Announces Start of Sixth Annual 'Leave Your Mark' Essay Contest
RevBits Delivers End-to-End Email Security - Defending from the Mail Server to the Edge User's Inbox
Frost & Sullivan Recognizes Leading Organizations with Prestigious 2022 Best Practices Awards
Religare Broking Moves its Corporate Office to Andheri East
"The only sustainable way we can get to 5 trillion is if the bottom 600 billion Indians are part of the process," said Dr. D Subbarao, Former Finance Secretary and RBI Governor
Comviva and Vietnamobile announce strategic partnership to power AI-led intelligent customer engagement
Union Bank of India launches Union Prerna 2.0 - EmpowerHim
Passion Gaming Orchestrates Real-Time Data-Based Decision Making With Tableau
Shanghai Electric Announces Continued Commitment to Promoting Friendship Between China and Pakistan on International Friendship Day
Azure Power Announces Appointment of Rupesh Agarwal as Chief Strategy & Commercial Officer
Merged Solcon-IGEL GROUP Launches New Website
City of Glasgow College, UK partners with Scottish Institute of Hospitality Sciences to strengthen their presence in India
NIA highlights four key magnets to attract foreign investors, pushing Thailand as a "Global Hub" for international startups and investors
Global Automotive Plastics Market Boosted by the Need to Minimize CO2 Emissions
Vantage partners UNHCR for global fundraising activity for refugees, matches donations dollar-for-dollar.
Experion Technologies and TRL Software UK's new JV promises safer roads using technology-driven solutions iROADS and iMAAP
DigiFT Launches Decentralized Security Token Exchange
Anirban Gupta joins Colliers as Managing Director, East India to drive business growth
PLDT fires up PH link of US-Transpacific Jupiter Cable system
SVKM's NMIMS School of Pharmacy & Technology Management, Shirpur Campus bags NBA Accreditation
Zimbabwe President Emmerson Mnangagwa launched US$500 million Zim Cyber City by UAE investor Mulk Int'l opens new investment opportunities for Indians
Tejas Networks awarded Rs 298 crore optical network contract by Power Grid Corporation of India Limited (PGCIL)
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS
Active Motif and EpiCypher Execute Cross-Licensing Agreement and End Ongoing Litigation Involving Targeted Transposition/CUT&Tag Technology for Epigenomics
Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology
Resulticks Named in 2022 GartnerÂ® Magic Quadrantâ¢ for Multichannel Marketing Hubs for the Sixth Year in a Row
Linear TV viewing down as online long form viewing time increases according to Omdia
Global Fund Reports Significant Progress in Breaking Down Human Rights-Related Barriers to HIV and TB Services
PERSISTENT LOSS OF SMELL DUE TO COVID-19 CLOSELY CONNECTED TO LONG-LASTING COGNITIVE PROBLEMS